Log in

NASDAQ:CNSTConstellation Pharmaceuticals Stock Price, Forecast & News

$37.39
-0.13 (-0.35 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$36.40
Now: $37.39
$38.97
50-Day Range
$33.38
MA: $38.69
$49.79
52-Week Range
$6.01
Now: $37.39
$59.49
Volume372,991 shs
Average Volume569,644 shs
Market Capitalization$1.56 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.62
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. It is also developing CPI-0209, which is in preclinical trials for the treatment of solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Read More
Constellation Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CNST
CUSIP21036U206
Phone617-714-0555

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$8.23 per share

Profitability

Net Income$-85,550,000.00

Miscellaneous

Employees82
Market Cap$1.56 billion
Next Earnings Date8/5/2020 (Estimated)
OptionableNot Optionable

Receive CNST News and Ratings via Email

Sign-up to receive the latest news and ratings for CNST and its competitors with MarketBeat's FREE daily newsletter.

Constellation Pharmaceuticals (NASDAQ:CNST) Frequently Asked Questions

How has Constellation Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Constellation Pharmaceuticals' stock was trading at $32.57 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CNST stock has increased by 14.8% and is now trading at $37.39. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Constellation Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Constellation Pharmaceuticals.

When is Constellation Pharmaceuticals' next earnings date?

Constellation Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Constellation Pharmaceuticals.

How were Constellation Pharmaceuticals' earnings last quarter?

Constellation Pharmaceuticals Inc (NASDAQ:CNST) posted its quarterly earnings results on Wednesday, May, 6th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.62) by $0.01. View Constellation Pharmaceuticals' earnings history.

What price target have analysts set for CNST?

8 analysts have issued 12 month price objectives for Constellation Pharmaceuticals' shares. Their forecasts range from $35.00 to $75.00. On average, they expect Constellation Pharmaceuticals' stock price to reach $50.29 in the next twelve months. This suggests a possible upside of 34.5% from the stock's current price. View analysts' price targets for Constellation Pharmaceuticals.

Has Constellation Pharmaceuticals been receiving favorable news coverage?

News articles about CNST stock have trended neutral recently, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Constellation Pharmaceuticals earned a daily sentiment score of 0.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news aboutConstellation Pharmaceuticals.

Are investors shorting Constellation Pharmaceuticals?

Constellation Pharmaceuticals saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 1,770,000 shares, a decrease of 11.9% from the April 30th total of 2,010,000 shares. Based on an average daily trading volume, of 373,400 shares, the days-to-cover ratio is currently 4.7 days. Currently, 7.7% of the shares of the company are short sold. View Constellation Pharmaceuticals' Current Options Chain.

Who are some of Constellation Pharmaceuticals' key competitors?

What other stocks do shareholders of Constellation Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Canopy Growth (CGC), Axsome Therapeutics (AXSM), AbbVie (ABBV), Arrowhead Pharmaceuticals (ARWR), Crispr Therapeutics (CRSP), Enphase Energy (ENPH), Novavax (NVAX), NVIDIA (NVDA) and Provention Bio (PRVB).

Who are Constellation Pharmaceuticals' key executives?

Constellation Pharmaceuticals' management team includes the following people:
  • Mr. Jigar Raythatha, Pres, CEO & Director
  • Ms. Emma Reeve, Sr. VP, CFO Treasurer & Sec. (Age 58)
  • Dr. Adrian M. Senderowicz, Sr. VP & Chief Medical Officer (Age 55)
  • Dr. Danny Reinberg Ph.D., Co-Founder
  • Dr. Yang Shi Ph.D., Co-Founder

When did Constellation Pharmaceuticals IPO?

(CNST) raised $80 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager.

What is Constellation Pharmaceuticals' stock symbol?

Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST."

Who are Constellation Pharmaceuticals' major shareholders?

Constellation Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include VR Adviser LLC (9.60%), Wellington Management Group LLP (5.60%), Cormorant Asset Management LP (4.88%), TRV GP LLC (3.67%), Regents of The University of California (3.58%) and BlackRock Inc. (3.14%). Company insiders that own Constellation Pharmaceuticals stock include Adrian Senderowicz, Alexandria Venture Investments, Anthony B Evnin, Emma Reeve, Group L P Column, James E Audia, James E Flynn, Karen Valentine, Mark A Goldsmith, Of The University Of C Regents and Patrick Trojer. View institutional ownership trends for Constellation Pharmaceuticals.

Which institutional investors are selling Constellation Pharmaceuticals stock?

CNST stock was sold by a variety of institutional investors in the last quarter, including TRV GP LLC, Cormorant Asset Management LP, Regents of The University of California, Casdin Capital LLC, Canada Pension Plan Investment Board, Two Sigma Investments LP, Morgan Stanley, and Soleus Capital Management L.P.. Company insiders that have sold Constellation Pharmaceuticals company stock in the last year include Adrian Senderowicz, Emma Reeve, James E Audia, Karen Valentine, Mark A Goldsmith, Of The University Of C Regents, and Patrick Trojer. View insider buying and selling activity for Constellation Pharmaceuticals.

Which institutional investors are buying Constellation Pharmaceuticals stock?

CNST stock was purchased by a variety of institutional investors in the last quarter, including VR Adviser LLC, Victory Capital Management Inc., Victory Capital Management Inc., Wellington Management Group LLP, BlackRock Inc., Vivo Capital LLC, Franklin Resources Inc., and Trustees of Princeton University. Company insiders that have bought Constellation Pharmaceuticals stock in the last two years include Alexandria Venture Investments, Anthony B Evnin, Group L P Column, and James E Flynn. View insider buying and selling activity for Constellation Pharmaceuticals.

How do I buy shares of Constellation Pharmaceuticals?

Shares of CNST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Constellation Pharmaceuticals' stock price today?

One share of CNST stock can currently be purchased for approximately $37.39.

How big of a company is Constellation Pharmaceuticals?

Constellation Pharmaceuticals has a market capitalization of $1.56 billion. The company earns $-85,550,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis. Constellation Pharmaceuticals employs 82 workers across the globe.

What is Constellation Pharmaceuticals' official website?

The official website for Constellation Pharmaceuticals is www.constellationpharma.com.

How can I contact Constellation Pharmaceuticals?

Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.